Related Experiment Video

Updated: Jul 11, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

[Depressive disturbances during antiviral therapy in patients with type C hepatitis]

T M Ignatova, M A Kinkul'kina, A O Morozov

    Klinicheskaia Meditsina
    |September 22, 2007
    PubMed

    Insights

    Hepatitis C patients undergoing antiviral therapy (AVT) frequently develop depression. Antidepressants effectively treated interferon-alpha (IFN-alpha)-induced depression, enabling completion of AVT.

    Area of Science:

    • Psychiatry
    • Hepatology
    • Pharmacology

    Context:

    • Chronic C hepatitis requires combined antiviral therapy (AVT) using interferon-alpha (IFN-alpha) and ribavirin.
    • Patients with chronic hepatitis C often have no prior psychiatric conditions.
    • Investigating the psychological impact of AVT is crucial for patient management.

    Purpose:

    • To study the clinico-psychopathological features of depressive disorder (DD) in patients with chronic hepatitis C during AVT.
    • To identify clinical differences between interferon-alpha-induced depression and endogenous DD.
    • To evaluate the efficacy of antidepressants in treating AVT-induced depression.

    Summary:

    • Depression developed in 43% of 91 patients with chronic hepatitis C during AVT.
    • Moderate to severe depression was prevalent, with distinct clinical features compared to endogenous depression.
    • Depression severity did not correlate with hepatitis C severity or AVT duration/type.

    Impact:

    • Antidepressants, including remeron, were effective in treating interferon-alpha-induced depression.
    • Successful management of depression allowed for the completion of AVT in all patients.
    • Findings highlight the importance of monitoring and treating depression during hepatitis C treatment.

    More Related Videos

    Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

    Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

    Published on: October 29, 2015

    Related Concept Videos

    Inhibitors of Viral Protein Synthesis01:30

    Inhibitors of Viral Protein Synthesis

    Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
    Hepatitis01:25

    Hepatitis

    Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
    Antiviral Nucleoside Inhibitors01:22

    Antiviral Nucleoside Inhibitors

    Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
    Viral Hepatitis I: Introduction01:28

    Viral Hepatitis I: Introduction

    Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
    Retrovirus Life Cycles01:10

    Retrovirus Life Cycles

    Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

    Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...